Product news from the 12/19/06 news brief

Share this article:
The FDA has approved SkyePharma’s Foradil Cerihaler (formoterol fumarate inhalation powder) for the treatment of asthma. Foradil Cerihaler has been co-developed by SkyePharma and Novartis, and is a trademark of Novartis. The FDA has approved EMD Pharmaceuticals’ Cyanokit (hydroxocobalamin, intravenous tubing and a sterile spike for reconstituting the drug product with saline) for the treatment of known or suspected cyanide poisoning. The approval, which is based on evidence of the drug's effectiveness when tested in animals, improves the nation's ability to respond to emergencies, including a potential attack by terrorists, the FDA said. The FDA warned yesterday that two patients taking Rituxan died from the rare brain infection progressive multifocal leukoencephalopathy or PML. The patients who died were receiving the drug as an off-label treatment for lupus. Rituxan, sold by Genentech and Biogen Idec was approved nearly 10 years ago as a treatment for non-hodgkins lymphoma. Sales of Rituxan were at $1.8 billion for 2005.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.